Tyrian (ASX TDX) have had recent success announcing validation of its proprietary TB diagnostic marker in a molecular diagnostic test to detect active tuberculosis (TB). The study was conducted by the Public Health Research Institute?s TB Centre in the US. It has patent protection till 2022. This company previously had ceased its relationship with Becton, Dickinson & Co and is now looking for a new partner to commercialise their test.
Tyrian has a current market cap of around $4m and needs funds (current rights issue)to continue development and commercialisation of it's products. This company would seem a good synergistic fit for Celestis to aquire would it not? A test for active TB complimenting it's test for latent TB. The sales and marketing team would love to have products that cover both active and latent TB.
CST Price at posting:
$2.50 Sentiment: LT Buy Disclosure: Held
